Bringing 3D cardiac tissues to high throughput for drug discovery screens
1. Cardiovascular disease is the number 1 cause of death worldwide. Novel cardiovascular drugs have a high failure rate of 91% in clinical trials. This failure rate is due to lack of proper cardiac models used to find new drugs. D...
1. Cardiovascular disease is the number 1 cause of death worldwide. Novel cardiovascular drugs have a high failure rate of 91% in clinical trials. This failure rate is due to lack of proper cardiac models used to find new drugs. Drug discovery studies rely mainly on 2D culture models, which have insufficient predictive value of the human heart. A new in vitro 3D model has been developed by assembling human cardiomyocytes into a three-dimensional strip configuration (3D cardiac strip) that better mimics the native heart tissue. However, this system is not compatible with the high throughput setting needed to perform drug discovery screens. River BioMedics has found a unique solution to miniaturize the human 3D cardiac strips and use them in a high-throughput assay. We combine two innovative technologies: human induced pluripotent stem cell (hiPSC)-cardiac cells and microfluidic systems. The Open-TOP microfluidic technology developed in the group of Prof. v.d. Berg from the University of Twente enables the culturing hundreds of culture chambers automatically and consistently, which is key in high throughput screens. This technology will enable the production and culture of 3D cardiac strips in large numbers, bringing 3D vitro models into a high throughput scale. The end users of this technology are pharma companies performing drug discovery activities and CROs providing drug discovery services. For commercialization of 3DCardiacHTS we plan to partner with an end-user and assess their requirements for the use of such high throughput technology, with the intention of securing their partnership at the end of the project In parallel we will discuss the various partnering options with identified potential Pharma partners and/or CROs the best financial deal structure for partnership on 3DCardiacHTS and consequently validate the best business model to pursue the commercialization of 3DCardiacHTS.ver más
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.